In Vitro Studies of BB-K8, a New Aminoglycoside Antibiotic

AUTOR(ES)

Bodey, Gerald P.

RESUMO

BB-K8, an aminoglycoside antibiotic which is a derivative of kanamycin, was tested in vitro against 466 clinical bacterial isolates. Over 90% of gram-negative bacilli, except Proteus spp., were inhibited by 3.12 μg of BB-K8 per ml. This antibiotic was consistently more active than kanamycin but less active than tobramycin or gentamicin. Unlike kanamycin, BB-K8 was active against Pseudomonas aeruginosa. Eleven of 19 isolates resistant to either gentamicin or tobramycin, or both, were susceptible to BB-K8.

Documentos Relacionados

• Comparative In Vitro Activity of Three Aminoglycosidic Antibiotics: BB-K8, Kanamycin, and Gentamicin
• In Vitro Comparison of Four Aminoglycoside Antibiotics: Sisomicin, Gentamicin, Tobramycin, and BB-K8
• Activity of BB-K8 (Amikacin) Against Clinical Isolates Resistant to One or More Aminoglycoside Antibiotics
• In Vitro Studies of Netilmicin, a New Aminoglycoside Antibiotic
• Rapid, Specific Microbiological Assay for Amikacin (BB-K8)